The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation.
S. J. Mandrekar
No relevant relationships to disclose
Y. Qi
No relevant relationships to disclose
K. Allen-Ziegler
No relevant relationships to disclose
S. L. Hillman
No relevant relationships to disclose
M. W. Redman
No relevant relationships to disclose
S. E. Schild
No relevant relationships to disclose
D. R. Gandara
No relevant relationships to disclose
A. A. Adjei
No relevant relationships to disclose